Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in EnglandMaureen Cleary, Karolina M. Stępień, Rachel Gould et al.|Orphanet Journal of Rare Diseases|2021Cited by 29